An Early Phase 1 interventional study of Blinded Study Medication - Condition 1 and Blinded Study Medication - Condition 2 in Healthy Volunteers, sponsored by Johns Hopkins University. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-12.
Sponsored by Johns Hopkins University · Early Phase 1, Interventional, and Basic science
This research is being done to evaluate the impact of various drugs and combinations of drugs on mood, pain, and performance.
This research is being done to evaluate the impact of various drugs and combinations of drugs on mood, pain, and performance. Participants will complete 1 screening visit and 7 study test sessions. During the study sessions the participant will receive a study drug that may contain blinded drugs or drug combinations. Participants will answer questions about how the participant feels, perform tasks that measure the participant's cognitive ability and experience of pain, and have heart rate and blood pressure measured. While not at the laboratory, participants will be asked to wear a wristwatch that measures sleep and activity and complete questions about sleep.
Johns Hopkins University is the lead sponsor of 1,783 studies on the registry; 313 are open to participants now.
Of its 203 completed or terminated interventional studies of FDA-regulated products, 140 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This is the single arm that will go through all within-subject dose conditions in a Latin-Square randomized order.
Drug: Blinded Study Medication - Condition 1
This is the single arm that will go through all within-subject dose conditions in a Latin-Square randomized order.
Drug: Blinded Study Medication - Condition 2
This is the single arm that will go through all within-subject dose conditions in a Latin-Square randomized order.
Drug: Blinded Study Medication - Condition 3
This is the single arm that will go through all within-subject dose conditions in a Latin-Square randomized order.
Drug: Blinded Study Medication - Condition 4
This is the single arm that will go through all within-subject dose conditions in a Latin-Square randomized order.
Drug: Blinded Study Medication - Condition 5
This is the single arm that will go through all within-subject dose conditions in a Latin-Square randomized order.
Drug: Placebo
Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
Also known as: stimulant, cannabinoid, benzodiazepine, opioid, sleep medication, over the counter (OTC) medication
Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
Also known as: stimulant, cannabinoid, benzodiazepine, opioid, sleep medication, over-the-counter (OTC) medication
Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
Also known as: stimulant, cannabinoid, benzodiazepine, opioid, sleep medication, over-the-counter (OTC) medication
Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
Also known as: stimulant, cannabinoid, benzodiazepine, opioid, sleep medication, over-the-counter (OTC) medication
Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
Also known as: stimulant, cannabinoid, benzodiazepine, opioid, sleep medication, over-the-counter (OTC) medication
Double blind administration of placebo.
Demand Intensity - Consumption of Blinded Drug at Unconstrained Price as Measured by a Demand Task
Consumption of blinded drug at unconstrained price as measured by a demand task. Minimum value is 0, maximum value is not constrained. Higher scores indicate more drug consumption at unconstrained price (a worse outcome).
Time frame: Upon completion of experimental session (~8 hours post drug administration)
Breakpoint - Maximum price paid for blinded drug as measured by a demand task
Maximum price paid for blinded drug as measured by a demand task. Minimum value is 0, maximum value is not constrained. Higher scores indicate higher price paid (a worse outcome).
Time frame: Upon completion of experimental session (~8 hours post drug administration)
Cold Pressor Pain - Seconds to withdraw hand from cold pressor
Seconds to withdraw hand from cold pressor laboratory pain task, where longer time periods reflect higher tolerance to pain.
Time frame: Baseline and 1, 2, 4, and 6 hours post drug administration
Cognitive Performance assessed by Digit Symbol Substitution Test (DSST)
Within-subject comparison of study conditions on the Digit Symbol Substitution Test (DSST), a measure of cognitive performance that is sensitive to drug effects, wherein lower percent scores reflect worse performance and suggest greater drug-related impairment.
Time frame: Baseline and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, and 8 hours post drug administration.
Drug Liking assessed by Visual Analog Scale of Drug Liking
Ratings on a visual analog scale of drug liking. Minimum value is 0 and maximum value is 100. Higher scores indicate greater drug liking (a worse outcome).
Time frame: Upon completion of experimental session (~9 hours post drug administration)
This study is withdrawn, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johns Hopkins University